Fostering culture and optimizing organizational structure for implementing model-based drug development

Journal of Clinical Pharmacology

Volumn 50, Issue 9, 2010, Pages

  Zhang, Liping ^a   Allerheiligen, Sandra R ^b   Lalonde, Richard L ^c   Stanski, Donald R ^d   Pfister, Marc ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c PFIZER INC   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

culture; implementation; Model based drug development; modeling and simulation; organizational structure; pharmacometrics

Indexed keywords

CULTURAL SENSITIVITY; DECISION MAKING; DRUG INDUSTRY; DRUG RESEARCH; MODEL; MODEL BASED DRUG DEVELOPMENT; ORGANIZATIONAL STRUCTURE; PHARMACOMETRICS; SHORT SURVEY; SIMULATION;

ANIMALS; COMPUTER SIMULATION; COOPERATIVE BEHAVIOR; DECISION MAKING, ORGANIZATIONAL; DRUG DESIGN; DRUG INDUSTRY; HUMANS; MODELS, THEORETICAL; ORGANIZATIONAL CULTURE; OWNERSHIP; PHARMACEUTICAL PREPARATIONS;

EID: 78449292215     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010376976     Document Type: Short Survey

References (14)

1. Stanski DR Model-based drug development: a FDA critical path opportunity. Paper presented at: the 14th Annual Meeting of the Population Approach Group in Europe, Pamplona, Spain, 2005.
2. Dykstra K., Pugh R., Krause A. Visualization Concepts to Enhance Quantitative Decision Making in Drug Development. J Clin Phamacol. 2010 ; 50 (suppl 1). 130S - 139S.
3. Romero K., Corrigan B., Tornoe CW, Gobburu JV, Meindert Danhof, Gillespie WR, Gastonguay MR, Meibohm B., Derendorf H. Pharmacometrics as a Discipline Is Entering the "Industrialization" Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success. J Clin Phamacol. 2010 ; 50 (suppl 1). 9S - 19S.
4. Stone J., Banefield C., Pfister M., et al. Model-Based Drug Development Survey Finds PharmacometricsImpacting Decision Making in the Pharmaceutical Industry. J Clin Phamacol. 2010 ; 50 (suppl 1). 20S - 30S.
5. Wetherington J., Pfister M., Banefield C., et al. Model-based drug development: strengths, weaknesses, opportunities and threats for broad implementation in drug development. J Clin Phamacol. 2010 ; 50 (suppl 1). 31S - 46S.
6. Sheiner LB Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997 ; 61: 275-291.
7. Suryawanshi S., Zhang L., Pfister M., Meibohm B., Healthcare PI The current role of model-based drug development. Expert Opin Drug Discov. 2010 ; 5: 311-321.
8. Allerheiligen S. Using Quantitative Pharmacology Levers to Optimize Drug Discovery and Development. Workshop on Quantitative Pharmacology, American Association of Pharmaceutical Sciences Annual Meeting, San Diego, CA, 2007.
9. Zhang L., Sinha V., Forgue ST, et al. Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn. 2006 ; 33: 369-393.
10. Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther. 2007 ; 82: 21-32.
11. Hatch MJ, Schultz M. Taking Brand Initiative: How Companies Can Align Strategy, Culture, and Identity Through Corporate Branding. 1 st ed. San Francisco, Calif: Jossey-Bass ; 2008.
12. Barrett JS, Fossler MJ, Cadieu KD, R. GM. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol. 2008 ; 48: 632-649.
13. Woodcock J. Precompetitive research: a new prescription for drug development. Clin Pharmacol Ther. 2010 ; 87: 521-523.
14. Gobburu J. Pharmacometrics, 2010. J Clin Pharmacol. THIS ISSUE.